Fear-conditioned analgesia is an important survival response mediated by substrates controlling nociception and aversion. Cannabinoid 1 (CB 1 ) receptors play an important role in nociception and aversion. However, their role in fear-conditioned analgesia has not been investigated. This study investigated the effects of systemic administration of the CB 1 receptor antagonist, SR141716A (1 mg ⁄ kg, ip), on fear-conditioned analgesia and conditioned aversion in rats. Twenty-four hours after receiving footshock, rats exhibited reduced formalin-evoked nociceptive behaviour, increased freezing and increased defecation when tested in the footshock apparatus, compared with non-footshocked formalin-injected rats. SR141716A attenuated fear-conditioned analgesia, freezing and defecation. Importantly, SR141716A had no effect on formalin-evoked nociceptive behaviour over an equivalent time period in rats not receiving footshock. SR141716A had no effect on contextually induced freezing during the first half of the test trial in rats receiving intra-plantar injection of saline. Administration of SR1417176A did, however, attenuate short-term extinction of contextually induced freezing and ultrasound emission in rats receiving intra-plantar saline, compared with vehicle-treated saline controls. These data suggest an important role for the CB 1 receptor in mediating fear-conditioned analgesia and provide evidence for differential modulation of conditioned aversive behaviour by CB 1 receptors during tonic, persistent pain.
Introduction
Fear-conditioned analgesia is an important component of the complex, coordinated defence response that improves an animal's chance of survival when confronted by a predator or an environmental threat. Experimental models of fear-conditioned analgesia involve exposure of rats to noxious thermal stimuli (Harris & Westbrook, 1994 , 1995 or footshock (Calcagnetti et al., 1987; Fanselow & Helmstetter, 1988) , and the measurement of formalin-evoked nociceptive responses 24 h later in the same apparatus. Opioid (Calcagnetti et al., 1987; Fanselow et al., 1989) and c-aminobutyric acid (GABA)-ergic (Fanselow & Helmstetter, 1988; Harris & Westbrook, 1995) mediation of fearconditioned analgesia, via modulation of descending inhibitory pain pathways (Kinscheck et al., 1984; Helmstetter, 1992) , has been demonstrated.
Cannabinoid 1 (CB 1 ) receptors are located throughout brain regions that are key components of the descending inhibitory pain pathway, and which are involved in mediating behavioural responses to unconditioned and conditioned aversive stimuli (Herkenham et al., 1991) . Systemic administration of cannabinoid agonists or their microinjection into the amygdala, periaqueductal grey (PAG) or rostral ventromedial medulla is anti-nociceptive in the tail-flick and formalin tests (for review see Finn & Chapman, 2004) . CB 1 receptors modulate behavioural responses to unconditioned aversive stimuli (Finn et al., 2003a (Finn et al., , 2004b and mediate extinction of conditioned aversive memory associated with noxious stimulation (Marsicano et al., 2002) . Despite the close functional association between the endocannabinoid receptor system and the endogenous opioid (Welch & Eads, 1999; Cichewicz & McCarthy, 2003; Finn et al., 2004a) and GABAergic (Meng et al., 1998; Manning et al., 2003) systems, the role of CB 1 receptors in mediating fear-conditioned analgesia has not been investigated.
The aim of the present study was to characterize the effects of systemic administration of the CB 1 receptor antagonist SR141716A on fear-conditioned analgesia and on conditioned aversion in the presence and absence of nociceptive tone.
Materials and methods

Animals
Male Lister-hooded rats (250-300 g, Charles River, UK) were housed in cages of four and maintained on a 12 : 12 h light : dark cycle (lights on at 07.00 h) with access to food and water ad libitum. Experiments were conducted between 09.00 h and 16.30 h according to the UK Home Office Animals (Scientific Procedures) Act 1986.
Experimental procedure
The experiment consisted of two phases, conditioning and testing, taking place 24 h apart. Subjects were randomly assigned to groups and the sequence of testing was randomized to minimize any confounding effects of the order of testing. On the conditioning day, rats were placed in a Perspex footshock ⁄ observation chamber (30 cm 3 ), and after 15 s they received 10 footshocks (0.4 mA, 1 s, Campden Instruments, UK) spaced 60 s apart. Fifteen seconds after the last footshock rats were returned to their home cage. We have previously shown that this footshock protocol results in robust conditioned aversive behaviour (Finn et al., 2003b) . Controls not receiving footshock were exposed to the Perspex chamber for an equivalent 9.5-min period. Twenty-four hours following removal from the observation chamber, rats received an intra-plantar injection of 50 lL formalin (2.5% in 0.9% saline) or 0.9% saline into the right hindpaw under brief isoflurane anaesthesia. This was followed immediately by ip injection of the CB 1 receptor antagonist, SR141716A (N-[piperidin-1-yl]-5-[4-chlorophenyl]-1-[2,4-dichlorophenyl]-4-methyl-1-H-pyrazole-3-carboxamide], NIMH Chemical Synthesis Programme: Lot LR-IX-101B, 1 mg ⁄ kg), or vehicle (ethanol : cremophor : saline in a ratio of 1 : 1 : 18) in a volume of 1 mL ⁄ kg. The dose of SR141716A and time of administration were chosen with a view to minimizing its effects on general behaviour as well as formalin-evoked nociceptive behaviour, and were based on our previous work (Finn et al., 2004b) and studies in the literature (Strangman et al., 1998; Hillard et al., 1999; Jarbe et al., 2002) . Systemic administration of this dose of SR141716A has been shown to block the behavioural effects of selective CB 1 receptor agonists as well as exogenously administered endocannabinoids (Hillard et al., 1999) . The design resulted in six experimental groups: footshock + formalin + vehicle (FS-Form-Veh); footshock + formalin + SR141716A (FS-Form-SR); no footshock + formalin + vehicle (no FS-Form-Veh); no footshock + formalin + SR141716A (no FS-Form-SR); footshock + saline + vehicle (FS-Sal-Veh); footshock + saline + SR141716A FS-Sal-SR). Following ip injection of SR141716A or vehicle, rats were returned to their home cage until 30 min post-formalin injection when they were placed in the Perspex observation chamber in which footshock was delivered on the conditioning day. A microphone was positioned above the chamber and connected to a bat detector (Mini-3, Ultra Sound Advice, UK) enabling detection of aversive ultrasonic vocalization in the 20-40 kHz range. A video camera was positioned under the Perspex chamber. Formalin-evoked nociceptive behaviour was scored for a period of 15 min according to the weighted composite pain scoring technique (CPS-WST 0,1,2 ) described by Watson et al. (1997) . The 30-45-min postformalin interval was chosen based on our previous studies, demonstrating that formalin-evoked nociceptive behaviour is stable over this time period (Finn et al., 2003a (Finn et al., , 2003b (Finn et al., , 2004a . The number of rears were also scored and distance moved was tracked using Ethovision software (Noldus, Netherlands). Faecal pellets were counted at the end of the trial and oedema was assessed by measuring the paw diameter pre-and postformalin with Vernier callipers. Duration of freezing (defined as the cessation of all visible movement except that necessary for respiration) and duration of ultrasonic vocalizations were also measured. All behavioural measurements were carried out by an experimenter blind to the treatments. Rats were killed by stunning and decapitation at the end of the trial.
Data analysis
All data are presented as means ± SEM. The CPS, freezing and ultrasonic vocalization data were analysed in 1-min time bins over the course of the entire 15-min test trial by two-factor anova, with group and time as the two factors. Subsequent two-factor anova on all formalin-treated groups (drug treatment and footshock as factors) or all footshock groups (drug treatment and formalin injection as factors) was performed on data collected during the first (0-7 min or 1-7 min) or second (7-15 min) parts of the test trial (i.e. 30-37 min or 37-45 min post-formalin). The choice of time bins was based on the duration and profile of fear-conditioned analgesia. Locomotor activity and defecation over the 15-min test trial were also analysed by two-factor anova. The Bonferroni post-hoc test was used to make multiple, pairwise group comparisons. The level of significance was set at P < 0.05.
Results
Effect of the CB 1 receptor antagonist SR141716A on fear-conditioned analgesia Intra-plantar injection of formalin produced robust licking, biting, shaking, flinching and elevation of the injected paw over the 15-min trial (Fig. 1A) . Saline-injected animals did not exhibit nociceptive behaviour (data not shown). Vehicle-treated, footshocked rats displayed significantly less formalin-evoked nociceptive behaviour during the first 7 min of the test trial, compared with vehicle-treated non-footshocked rats receiving formalin (P < 0.05; Fig. 1B ). Thus, contextual cues paired with shock were effective in producing fearconditioned analgesia. SR141716A-treated, footshocked rats displayed significantly more formalin-evoked nociceptive behaviour 1-7 min following placement in the observation chamber, compared with footshocked rats receiving vehicle (P < 0.05; Fig. 1B ). Importantly, there was no significant difference in formalin-evoked nociceptive behaviour in non-footshocked rats receiving SR141716A and those receiving vehicle during this period ( Fig. 1B) . Attenuation of fear-conditioned analgesia by SR141716A was not observed during the first minute after placement in the test arena ( Fig. 1A) .
Effects of the CB 1 receptor antagonist SR141716A on contextually induced freezing and ultrasound emission in formalin-and saline-treated rats Rats that did not receive footshock on day 1 did not display contextually induced freezing ( Fig ( Fig. 3) during the test trial 24 h later. Vehicle-treated rats that had received footshock and intra-plantar injection of formalin displayed less contextually induced freezing and ultrasound emission over the course of the test trial compared with vehicle-treated, footshocked rats receiving intra-plantar saline. Analysis of behaviour in formalintreated rats over the 1-7-min period during which SR141716A attenuated fear-conditioned analgesia revealed that systemic administration of SR141716A significantly reduced contextually induced freezing (P < 0.01; Fig. 2B ) but not ultrasound emission (Fig. 3) . In contrast, systemic administration of SR141716A had no significant effect on contextually induced freezing in rats receiving intra-plantar injection of saline during the first 7 min of the test trial ( Fig. 2A) . However, SR141716A significantly increased the duration of freezing and ultrasound emission over the second half of the trial (7-15 min) in rats receiving intra-plantar injection of saline, compared with vehicle-treated saline controls (P < 0.01; Figs 2A and 3) . Thus, blockade of CB 1 receptors prolonged contextually induced freezing and ultrasound emission in footshocked rats receiving intra-plantar injection of saline.
Effects of SR141716A and intra-plantar injection of formalin on locomotor activity, defecation and hindpaw oedema in conditioned and unconditioned rats SR141716A significantly reduced rearing in rats that had received footshock and intra-plantar injection of saline, compared with vehicle-treated controls (19.5 ± 9.6 vs. 42.8 ± 4.3; P < 0.05), but had no effect in footshocked rats receiving formalin. Intra-plantar injection of formalin significantly reduced rearing in vehicle-treated footshocked rats, compared with vehicle-treated footshocked rats receiving intra-plantar injection of saline (6.6 ± 2.7 vs. 42.8 ± 4.3; P < 0.001). SR141716A had no significant effect on distance moved in footshocked rats receiving intra-plantar injection of formalin or saline or in non-footshocked rats receiving formalin injection (data not shown).
Analysis of defecation revealed a significant footshock-drug treatment interaction in rats receiving intra-plantar injection of formalin (F 1,22 ¼ 14.7; P ¼ 0.0009). Vehicle-treated rats that had received footshock and formalin displayed significantly increased defecation, compared with vehicle-treated non-footshocked rats receiving formalin (4.6 ± 0.6 vs. 1.8 ± 0.6; P < 0.05). Systemic administration of SR141716A significantly attenuated this footshock-induced increase in defecation in formalin-treated rats (4.6 ± 0.6 vs. 1.6 ± 0.5; P < 0.05). In contrast, SR141716A had no significant effect on defecation in rats that had received footshock and intra-plantar injection of saline.
Intra-plantar injection of formalin evoked a significant oedema of the hindpaw in vehicle-treated rats that had received footshock (change in paw diameter ¼ 1.43 ± 0.08 mm), compared with vehicletreated footshocked rats receiving intra-plantar injection of saline (change in paw diameter ¼ 0.48 ± 0.26 mm). Neither SR141716A administration nor footshock had a significant effect on formalinevoked hindpaw oedema (data not shown).
Discussion
This study provides the first evidence for a role of CB 1 receptors in mediating fear-conditioned analgesia. Systemic administration of SR141716A attenuated fear-conditioned analgesia manifested over the first 7 min of the trial with the exception of the first minute. Fearconditioned analgesia can also be attenuated following systemic administration of l-opioid receptor antagonists or benzodiazepines (Fanselow & Helmstetter, 1988; Harris & Westbrook, 1994) . Because SR141716A has no appreciable affinity for either opioid or GABA receptors, our data suggest that the endocannabinoid receptor system also plays a role in fear-conditioned analgesia. We propose that the endocannabinoid system acts in concert with the endogenous opioid system to mediate the expression of fear-conditioned analgesia in a similar manner to the functional association between the endogenous opioid and cannabinoid systems during pain modulation (Welch & Eads, 1999; Cichewicz & McCarthy, 2003; Finn et al., 2004a) . The . P < 0.01 for FS-Sal-SR vs. FS-Sal-Veh from 7 to 15 min (two-way anova: F 1,22 ¼ 5.9; P ¼ 0.02 followed by Bonferroni post-hoc test); ***P < 0.001 vs. no FS-Form-Veh (two-way anova: F 1,22 ¼ 12.9; P ¼ 0.002 followed by Bonferroni post-hoc test); ++ P < 0.01 vs. FS-Form-Veh (two-way anova: F 1,22 ¼ 7.3; P ¼ 0.013 followed by Bonferroni post-hoc test). Non-footshocked rats displayed little or no freezing. close association between the opioid and cannabinoid systems and the GABAergic system during nociceptive processing (Meng et al., 1998; Manning et al., 2003) supports the role of such an integrated system in the expression of fear-conditioned analgesia. SR141716A was administered systemically and may therefore have exerted its effects by blocking CB 1 receptors located in the periphery or in the central nervous system. There is, however, strong evidence that the majority of fear-conditioned analgesia is under supra-spinal control (Calcagnetti et al., 1987) , and intra-cerebral administration of l-opioid receptor antagonists or midazolam (Fanselow et al., 1989; Harris & Westbrook, 1995) and lesion of key brain regions (Kinscheck et al., 1984; Helmstetter, 1992) completely attenuates fear-conditioned analgesia. While the neural substrates involved in CB 1 receptormediated fear-conditioned analgesia remain to be elucidated, one may hypothesize that endogenous cannabinoids and opioids acting in concert on GABAergic neurons in key brain regions, such as the amygdala and ⁄ or PAG, may mediate this important survival response.
The dose of SR141716A administered (1 mg ⁄ kg) blocks the behavioural effects of selective CB 1 receptor agonists, as well as the endocannabinoid anandamide (Hillard et al., 1999) . Although SR141716A has been shown to block vanilloid receptor (VR1)mediated effects at high concentrations in vitro , such effects have not been reported in vivo Jia et al., 2002; Palazzo et al., 2002; del Carmen Garcia et al., 2003) . Thus, it is unlikely that the effects of SR141716A on fear-conditioned analgesia were VR1-mediated.
SR141716A failed to attenuate the analgesia manifested during the first minute of the test. It is likely that this immediate and brief analgesic response results from the reinstatement of a short-lived naloxone-and midazolam-insensitive analgesic response that is elicited by exposure to a novel environment (Harris & Westbrook, 1994) . Our results extend these findings by demonstrating that this analgesic response is also CB 1 insensitive.
The effects of SR141716A on fear-conditioned analgesia were not compromised by any overt effects on locomotor activity. Moreover, administration of SR141716A had no effect on formalin-evoked nociceptive behaviour per se in non-conditioned rats over an equivalent time period. Inverse agonist effects of SR141716A have been reported in vitro (Meschler et al., 2000) ; however, its lack of effect on locomotor activity and formalin-evoked nociceptive behaviour argues against such an effect occurring in the present in vivo study. Evidence in the literature for the effects of SR141716A on formalin-evoked nociceptive behaviour in rats is equivocal with reports of both enhanced and reduced nociceptive behaviour following systemic administration. These discrepancies may be due to differences in rat strain, time of drug administration or scoring method. In agreement with our present study, Strangman et al. (1998) demonstrated that SR141716A (1 mg ⁄ kg, ip), administered 5 min after formalin injection, did not alter nociceptive behaviour 30 min postformalin.
An important finding of this study is that levels of nociception have an important bearing on the nature and extent to which CB 1 receptor activation modulates contextually induced freezing behaviour, ultrasound emission and defecation. Contextually induced ultrasound emission was markedly reduced in formalin-treated rats and was not affected by SR141716A during the 1-7-min period. Blockade of the CB 1 receptor, however, reduced freezing behaviour and attenuated fear-induced increases in defecation in parallel with attenuation of fear-conditioned analgesia, corroborating earlier evidence for a close relationship between freezing (as a measure of fear) and analgesia (Fanselow & Helmstetter, 1988; Helmstetter, 1992) . Previous studies have shown that systemic administration of SR141716A results in increased defecation and intestinal motility in rats under basal conditions (Izzo et al., 1999) . Here we demonstrate an attenuation of fear-induced defecation by SR141716A, which suggests an altered modulation of defecation by the endocannabinoid system under these conditions. In contrast to formalin-treated rats, SR141716A had no effect on contextually induced freezing in rats receiving intra-plantar injection of saline during the first half of the trial and had no effect on defecation in saline-injected rats. Thus, the presence of nociceptive tone has an important bearing on the extent to which these two indices of fear are modulated by the endocannabinoid system.
Although SR141716A had no effect on freezing and ultrasound emission during the first half of the test in rats receiving intraplantar injection of saline, SR141716A prolonged the expression of these behaviours during the second half of the trial. These data suggest that CB 1 receptor activation is not involved in the immediate expression of aversive behaviour upon exposure to the conditioned stimulus but does, however, play a role in the extinction of contextually induced aversive responses. These findings corroborate work demonstrating that systemic administration of SR141716A reduces both short-term and long-term extinction of freezing in mice (Marsicano et al., 2002) .
This study provides evidence of a role for the CB 1 receptor in mediating fear-conditioned analgesia. Furthermore, modulation of contextually induced aversive behaviour and extinction by the CB 1 receptor was dependent on the level of nociception. These results suggest an important role of the CB 1 receptor within the framework of the perceptual-defensive-recuperative model originally proposed by Bolles & Fanselow (1980) .
